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Abstract A series of rhodanine 3-carboxyalkanoic acid
derivatives possessing 4′-(N,N-dialkyl-amino or diphenyla-
mino)-benzylidene moiety as a substituent at the C-5 posi-
tion were synthesised and their antibacterial activity was
screened. All the rhodanine derivatives showed bacterio-
static or bactericidal activity to the reference gram-positive
bacterial strains, but lack of activity to the reference Gram-
negative bacterial strains and yeast strains was observed.
Keywords Rhodanine ● Thiazolidine-4-one ● Rhodanine-3-
acetic acid ● Antibacterial activity
Introduction
The 2-thiazolidine-4-one derivatives traditionally named
rhodanine have been known for over 100 years, and due to
their fascinating properties they are still examined (Lesyk
and Zimenkovsky 2004). These compounds have a broad
spectrum of biological effects (Jain et al. 2012). Rhodanine
derivatives show antimalarial (Kumar et al. 2007), anti-
tubercular (Alegaon et al. 2012), cytotoxic (Chandrappa
et al. 2009), antitumor (Rao et al. 2011; Lesyk et al. 2011),
antiviral (Kaminskyy 2015), and antibacterial activity
(Bhatti et al. 2013; Kavitha et al. 2006; Song et al. 2014).
The research to obtain new antibacterial compounds is
vitally important. Recently, due to excessive and improper
use of antibiotics, there has been an increasing rate of
antibiotic resistance in the bacterial strains (Woodford
2003), thus new groups of compounds which may be useful
as antibacterial agents have been examined. A few reports
has been published regarding the rhodanine derivatives with
a carboxyalkyl acid moiety at the N-3 position (Xu et al.
2012). Biological activity of hybrid compounds possessing
chalcone and rhodanine-3-acetic acid has been also studied
(Chen et al. 2010). Such hybrids demonstrated synergistic
effect. Antibacterial activity of rhodanine derivatives and
their oxygen analogues derived from 2,4-thiazolidinedione
was also compared (Zvarec et al. 2012). However, the
results of present study suggested that rhodanine derivatives
showed greater antibacterial activity than their analogues
from the 2,4-thiazolidinedione group having at the C-2
position exocyclic oxygen atom. It was shown that the
activity of the rhodanine derivative correlates with the size
of the substituent at the C-5 position (Pardasani et al. 2001).
The research conducted by Miao et al. (2013) and Patel
et al. (2013) indicated that antibacterial activity of the acid
derivatives occurred when a major hydrophobic group was
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introduced to the arylidene substituent at the C-5 position.
The best results were achieved when an aryl group addi-
tionally with an electron-withdrawing group was intro-
duced. The rhodanine derivatives possessing a 4-(N,N-
dimethylamino)-benzylidene substituent at the C-5 position
were also examined. These compounds acted as β-lactamase
inhibitors (Grant et al. 2000). Taking into account the data
presented by other authors, we decided to synthesise a series
of derivatives having carboxyalkyl (acetic, propionic,
butyric) acid fragment at N-3 position and benzylidene
para-substituent with dimethyloamino, diethylamino, dibu-
thyloamino or diphenylamino group at C-5 position.
Chemistry
Our initial research proved that the antibacterial activity of
the rhodanine derivatives which have carboxyalkyl frag-
ment at N-3 position was more effective than the com-
pounds with a substituent containing an amino group at C-5
position. We synthesised a series of rhodanine derivatives
with a carboxyalkyl acid radical at N-3 position (acetic,
propionic, butyric, caproic). The synthesis of the 3-
carboxyalkylrhodanine acids (Scheme 1) was conducted
according to the modiﬁed procedure proposed by Körner
(1908) at the beginning of the 20th century.
The synthesised compounds underwent Knoevenagel con-
densation with 4-diethylaminobenzoic, 4-dibutylaminobenzoic
aldehydes and 4-diphenylaminobenzoic aldehyde with trie-
thylamine as a catalyst. Quaternary ammonium salts, the
intermediates obtained during reactions, were not isolated but
transformed to appropriate acids with hydrochloric acid
(Scheme 2).
Material and methods
All reagents for the synthesis of rhodanine derivatives were
purchased from Sigma-Aldrich and used without further
puriﬁcation.
Melting point (uncorrected) has been determined on the
Boetius apparatus. The IR spectrum has been recorded with
Jasco FT IR-670 Plus spectrophotometer in the KBr disk.
The NMR spectra were obtained in CDCl3 on the Bruker
Avance III HD spectrometer operating at 400.17MHz (1H)
and 100.62 MHz (13C) and the Varian Mercury-VX
300 spectrometer operating at 300.08 MHz (1H) and
75.46MHz (13C), the chemical shifts (ppm) have been
referenced to lock out the signal of the solvent, J has been
expressed in Hz.
The MS analyses were obtained on the AmaZon ETD
mass spectrometer (Bruker Daltonics, Bremen, Germany).
Scan parameters: scan range 100–1000 m/z, positive ioni-
sation mode. CID fragmentation were in the ion trap
analyser with the aid of helium gas. The collision energy
was set to ca. 1 eV. The samples were introduced into the
mass spectrometer in a CH3OH:CHCl3 1:1 solution with
0.1% HCOOH acidiﬁcation.
General procedure of rhodanine-3-alkanoic acids
synthesis
The solution of 11.22 g (0.2 mol) potassium hydroxide in
50 cm3 of water was added to the suspension of 0.1 mol of
the appropriate amino acid (aminoethanoic acid, 3-
aminopropanoic acid, 4-aminobutanoic acid and 6-
aminohexanoic acid). The resulting solution was cooled to
5 °C and 7.6 g (0.1 mol) carbon disulphide was added. The
content of the ﬂask was mixed at 5 °C for 7 h. The cooling
bath was removed and mixing was continued in room
temperature for 20 h.
1a - n = 1
1b - n = 2
1c - n = 3






























R = -C2H5, -C4H9, -C6H5























3a - n = 1, R = -C2H5
3b - n = 2, R = -C2H5
3c - n = 3, R = -C2H5
3d - n = 3, R = -C2H5
4a - n = 1, R = -C4H9
4b - n = 2, R = -C4H9
4c - n = 3, R = -C4H9
5a - n = 1, R = -C6H5
5b - n = 2, R = -C6H5
5c - n = 3, R = -C6H5
Scheme 2 Rhodanine-3-carboxyalkyl acid condensation with
aldehydes
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The solution of 9.45 g (0.1 mol) chloroacetic acid in 50
cm3 water was added to the resulting solution. The solution
was mixed for 7 h at the temperature below 15 °C. Next, the
solution of 60 cm3 hydrochloric acid in 100 cm3 of water
was added to the ﬂask content. The resulting mixture was
heated to 90 °C and kept at the temperature for 20 min.
After cooling, a sediment was received, which was drained
and crystallised from water.
General procedure of rhodanine-3-alkanoic acids
condensation with aldehydes
0.005 mol of appropriate rhodanine-3-alkanoic
acid, 5 g molecular sieves 4 A, 25 cm3 isopropyl alcohol,
0.0055 mol appropriate aldehyde and 2.53 g (0.025 mol)
triethylamine were placed in a ﬂask. The mixture was
heated under a reﬂux condenser for 5 h in nitrogen. After
heating, the solution was ﬁltered hot. The permeate was
cooled and 50 cm3 of 2M hydrochloric acid solution was
added. The resulting sediment was ﬁltered using Büchner




m.p. 239–241 °C, yield 43.48%, MS [M+1]+—351.1, IR
cm-3: 1719.3C=O, 1699.9C=O conj., 1612.2, C=C exo.,
1322.9 C–N, 1185.1C=S, 1H NMR(400MHz,
CDCl3+MeOD), δ ppm, 7.66 (s, 1H,=CH–Ar), 7.37 (d, J
= 8.97 Hz, 2H, Ar–H), 6,70 (d, J= 9.00 Hz, 2H, Ar–H),
4.81 (s, 2H, HOOC–CH2–N), 3.43 (q, 4H, N(CH2CH3)2),
1.20 (t, 6H, N(CH2CH3)2)
13C NMR (101MHz,
CDCl3+MeOD), δ ppm, 12.35 (N(CH2CH3)2), 44.61
(CH2–N), 47.70 (N(CH2CH3)2), 111.67 (Ar–C), 114.09
(Ar–C), 119.93 (Ar–C), 133.78 (Ar–C), 135.65 (=CH–Ar),




m.p. 202–204 °C, yield 54.70%, MS [M+1]+—365.1, IR
cm-3: 1716.2C=O, 1700.9C=O conj., 1610.3, C=C exo.,
1331.6 C–N, 1199.5C=S, 1H NMR(400MHz, CDCl3), δ
ppm, 7.69 (s, 1H,=CH–Ar), 7.40 (d, J= 9.00 Hz, 2H,
Ar–H), 6,72 (d, J= 9.09 Hz, 2H, Ar–H), 4.45 (t, 2H,
HOOC–CH2–CH2–N), 3.46 (q, 4H, N(CH2CH3)2), 2.85 (t,
2H, HOOC–CH2–CH2–N), 1.24 (t, 6H, N(CH2CH3)2)
13C
NMR (101MHz, CDCl3), δ ppm, 12.57 (N(CH2CH3)2),
30.97 (CH2–CH2–N), 39.45 (CH2–CH2–N), 44.70(N
(CH2CH3)2), 111.70 (Ar–C), 114.51 (Ar–C), 120.17
(Ar–C), 133.72 (Ar–C), 135.23 (=CH–Ar), 149.82 (S–




m.p. 155–157 °C, yield 17.06%, MS [M+1]+—379.1, IR
cm-3: 1716.3C=O, 1693.2C=O conj., 1610.2C=C exo.,
1340.3 C–N, 1194.7C=S, 1H NMR(400MHz, CDCl3), δ
ppm, 7.67 (s, 1H,=CH–Ar), 7.39 (d, J= 8.84 Hz, 2H,
Ar–H), 6,72 (d, J= 9.04 Hz, 2H, Ar–H), 4.21 (t, 2H,
HOOC–CH2–CH2–CH2–N), 3.45 (q, 4H, N(CH2CH3)2),
2.45 (t, 2H, HOOC–CH2–CH2–CH2–N), 2.09 (q, 2H,
HOOC–CH2–CH2–CH2–N), 1.26 (t, 6H, N(CH2CH3)2)
13C
NMR (101MHz, CDCl3), δ ppm, 12.58 (N(CH2CH3)2),
22.28 (CH2–CH2–CH2–N), 31.17 (CH2–CH2–CH2–N),
43.43 (CH2–CH2–CH2–N), 44.67 (N(CH2CH3)2), 111.66
(Ar–C), 114.74 (Ar–C), 120.22 (Ar–C), 133.66 (Ar–C),
134.94 (=CH–Ar), 149.75 (S–C=CH), 168.23 (N–C=O),
177.79 (HOOC–), 193.38 (S=C–S)
3d/ 5-(4′-N,N-diethylaminobenzylidene)-rhodanine-3-
caproic acid
m.p. 135–137 °C, yield 32.96%, MS [M+1]+—407.1, IR
cm-3: 1717.3C=O, 1702.8C=O conj., 1615.1C=C exo.,
1327.7 C–N, 1195.7C=S, 1H NMR(400MHz, CDCl3),
δ ppm,11.25 (br. s HOOC–) 7.66 (s, 1H,=CH–Ar), 7.39
(d, J= 8.97 Hz, 2H, Ar–H), 6,72 (d, J= 8.48 Hz, 2H,
Ar–H), 4.13 (t, 2H, HOOC–CH2–CH2–CH2–CH2–
CH2–N), 3.45 (q, 4H, N(CH2CH3)2), 2.39 (t, 2H, HOOC–
CH2–CH2–CH2–CH2–CH2–N), 1.74 (m, 4H, HOOC–CH2–
CH2–CH2–CH2–CH2–N), 1.43 (m, 2H, HOOC–CH2–CH2–
CH2–CH2–CH2–N), 1.25 (t, 6H, N(CH2CH3)2)
13C NMR
(101MHz, CDCl3), δ ppm, 12.58 (N(CH2CH3)2), 24.19
(CH2–CH2–CH2–CH2–CH2–N), 26.20 (CH2–CH2–
CH2–CH2–CH2–N), 26.62 (CH2–CH2–CH2–CH2–CH2
–N), 44.21((CH2–CH2–CH2–CH2–CH2–N), 44.73 (N(CH2
CH3)2), 111.72 (Ar–C), 115.10 (Ar–C), 120.30 (Ar–C),
133.59 (Ar–C), 134.64 (=CH–Ar), 149.60 (S–C=CH),
168.14 (N–C=O), 179.47 (HOOC–), 193.33 (S=C–S)
4a/ 5-(4′-N,N-dibutylaminobenzylidene)-rhodanine-3-
acetic acid
m.p. 191–194 °C, yield 23.0%, MS [M+1]+—407.1, IR
cm-3: 1716.3C=O, 1698.0C=O conj., 1636.3C=C exo.,
1324.9 C–N, 1184.1C=S, 1H NMR(400MHz, CDCl3), δ
ppm, 7.72 (s, 1H,=CH–Ar), 7.40 (d, J= 8.96 Hz, 2H,
Ar–H), 6,72 (d, J= 7.64 Hz, 2H, Ar–H), 4.95 (s, 2H,
HOOC–CH2–N), 3.37 (t, 4H, N(CH2CH2CH2CH3)2), 1.63
(q, 4H, N(CH2CH2CH2CH3)2), 1.39 (m, 4H, N
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(CH2CH2CH2CH3)2), 0.99 (t, 6H, N(CH2CH2CH2CH3)2)
13C NMR (101MHz, CDCl3), δ ppm, 13.92 (N
(CH2CH2CH2CH3)2), 20.26 (N(CH2CH2CH2CH3)2), 29.32
(N(CH2CH2CH2CH3)2), 44.25 (–CH2–N), 51.01 (N
(CH2CH2CH2CH3)2), 112.02 (Ar–C), 114.11 (Ar–C),
120.22 (Ar–C), 133.68 (Ar–C), 135.70 (=CH–Ar), 150.17




m.p. 163–165 °C, yield 21.99%, MS [M+1]+—421.2, IR
cm-3: 1727.9C=O, 1698.0C=O conj., 1610.3C=C exo.,
1336.4 C–N, 1189.9C=S, 1H NMR(400MHz, CDCl3), δ
ppm, 7.68 (s, 1H,=CH–Ar), 7.38 (d, J= 9.18 Hz, 2H,
Ar–H), 6,69 (d, J= 8.80 Hz, 2H, Ar–H), 4.46 (t, 2H,
HOOC–CH2–CH2–N), 3.37 (t, 4H, N(CH2CH2CH2CH3)2),
2.86 (t, 2H, HOOC–CH2–CH2–N), 1.62 (q, 4H, N
(CH2CH2CH2CH3)2), 1.39 (q, 4H, N(CH2CH2CH2CH3)2),
1.02 (t, 6H, N(CH2CH2CH2CH3)2)
13C NMR (101MHz,
CDCl3), δ ppm, 13.94 (N(CH2CH2CH2CH3)2), 20.27 (N
(CH2CH2CH2CH3)2), 29.37 (N(CH2CH2CH2CH3)2), 30.95
(CH2–CH2–N), 39.45 (CH2–CH2–N), 50.87 (N
(CH2CH2CH2CH3)2), 111.82 (Ar–C), 114.41 (Ar–C),
120.06 (Ar–C), 133.64 (Ar–C), 135.23 (=CH–Ar), 150.22




m.p. 134–136 °C, yield 25.23%, MS [M+1]+—435.1,
IR cm-3: 1710.5C=O, 1691.3C=O conj., 1637.3C=C
exo., 1333.5 C–N, 1193.7C=S, 1H NMR(400MHz,
CDCl3), δ ppm, 11.00 (br. s, 1H, HOOC–) 7.66 (s, 1H,
=CH–Ar), 7.38 (d, J= 8.97 Hz, 2H, Ar–H), 6.67
(d, J= 9.05 Hz, 2H, Ar–H), 4.21 (t, 2H, HOOC–
CH2–CH2–CH2–N), 3.36 (t, 4H, N(CH2CH2CH2
CH3)2), 2.45 (t, 2H, HOOC–CH2–CH2–CH2–N),
2.09 (t, 2H, HOOC–CH2–CH2–CH2–N), 1.62 (q, 4H,
N(CH2CH2CH2CH3)2), 1.39 (m, 4H, N(CH2CH2CH2
CH3)2), 0.99 (t, 6H, N(CH2CH2CH2CH3)2)
13C NMR
(101MHz, CDCl3), δ ppm, 13.94 (N(CH2CH2CH2
CH3)2), 20.27 (N(CH2CH2CH2CH3)2), 22.27 (CH2–
CH2–CH2–N), 29.38 (N(CH2CH2CH2CH3)2), 31.21 (CH2–
CH2–CH2–N), 43.43 (CH2–CH2–CH2–N), 50.85 (N
(CH2CH2CH2CH3)2), 111.78 (Ar–C), 114.66 (Ar–C),
120.13 (Ar–C), 133.58 (Ar–C), 134.93 (=CH–Ar), 150.15




m.p. 240–242 °C, yield 64.27%, MS [M+1]+—447.1, IR
cm-3: 1724.1C=O, 1706.7C=O conj., 1634.4C=C exo.,
1329.7 C–N, 1192.7C=S, 1H NMR(400MHz, CDCl3), δ
ppm, 7.76 (s, 1H,=CH–Ar), 7.53 (d, J= 8.96 Hz, 2H,
Ar–H), 7.44–7.40 (m. 6H Ar), 7.25–7.18 (m, 6H Ar), 4.73
(s, 2H, HOOC–CH2–N)
13C NMR (101MHz, CDCl3), δ
ppm, 43.46 (–CH2–N), 39.87 (CH2–CH2–N), 117.67,
118.64, 119.67, 124.97, 125.85. 125.94, 125.66, 126.87,
129.05, 130.47, 130.50, 131.76, 133.32, 134.47, 166.92,
(Ar–C), 145.98 (=CH–Ar), 150.65 (S–C=CH), 167.63 (N–
C=O), 191.02 (HOOC–), 193.33 (S=C–S)
5b/ 5-(4′-N,N-diphenylaminobenzylidene)-rhodanine-3-
propionic acid
m.p. 212–215 °C, yield 76.09%, MS [M+1]+—461.1 IR
cm-3: 1733.7C=O, 1706.7C=O conj., 1637.3C=C exo.,
1338.4 C–N, 1193.7C=S, 1H NMR(400MHz,
CDCl3+MeOD), δ ppm, 7.61 (s, 1H,=CH–Ar), 7.32–7.23
(m. 6H Ar), 7.14–7.12 (m, 6H Ar), 6,98 (d, J= 8.76 Hz,
2H, Ar–H), 4.37 (t, 2H, HOOC–CH2–CH2–N), 2.71
(t, 2H, HOOC–CH2–CH2–N)
13C NMR (101MHz, CDCl3
+MeOD), δ ppm, 30.97 (–CH2–CH2–N), 39.87 (CH2–
CH2–N), 118.24, 120.30, 124.97, 125.22, 126.05, 129.66,
132.39, 133.77 (Ar–C), 146.04 (=CH–Ar), 150.46 (S–




m.p. 137–140 °C, yield 75.33%, MS [M+1]+—475.1, IR
cm-3: 1721.2C=O, 1700.9C=O conj., 1638.23C=C
exo., 1330.6 C–N, 1193.7C=S, 1H NMR(400MHz,
CDCl3), δ ppm, 10.90 (br. s, HOOC–), 7.67 (s, 1H,=
CH–Ar), 7.37–7.33 (m, 6H Ar), 7.19–7.16 (m, 6H Ar),
7.05 (d, J=8.80 Hz, 2H, Ar–H), 4.23 (t, 2H, HOOC–
CH2–CH2–CH2–N), 2.47 (t, 2H, HOOC–CH2–CH2–
CH2–N), 2.10 (q, 2H, HOOC–CH2–CH2–CH2–N)
13C
NMR (101MHz, CDCl3), δ ppm, 22.24 (CH2–CH2–CH2
–N), 31.10 (CH2–CH2–CH2–N), 43.50 (CH2–CH2–CH2
–N), 118.50, 120.43, 124.99, 125.41, 126.09, 129.72,
132.40, 133.58 (Ar–C), 146.14 (=CH–Ar), 150.40 (S–
C=CH), 168.12 (N–C=O), 177.75 (HOOC–), 193.27
(S=C–S)
Antibacterial activity assay in vitro
The 5-substituted derivatives of rhodanine-3-carboxyalkyl
acids were screened for antibacterial and antifungal
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activities by micro-dilution broth method using Mueller-
Hinton broth and Mueller-Hinton broth with 5% lysed
sheep blood for growth of non-fastidious and fastidious
bacteria, respectively or Mueller-Hinton broth with 2%
glucose for growth of fungi. Minimal inhibitory con-
centration (MIC) of the tested derivatives were evaluated for
the panel of the reference microorganisms from American
Type Culture Collection (ATCC), including Gram-negative
bacteria (Escherichia coli ATCC 25922, Salmonella typhi-
murium ATCC14028, Klebsiella pneumoniae ATCC
13883, Pseudomonas aeruginosa ATCC 9027, Proteus
mirabilis ATCC 12453), gram-positive bacteria (Staphylo-
coccus aureus ATCC 25923, Staphylococcus aureus ATCC
6538, Staphylococcus epidermidis ATCC 12228, Micro-
coccus luteus ATCC 10240, Bacillus subtilis ATCC 6633,
Bacillus cereus ATCC 10876, Streptococcus pyogenes
ATCC 19615, Streptococcus pneumoniae ATCC 49619,
Streptococcus mutans ATCC 25175), and fungi (Candida
albicans ATCC 10231, Candida parapsilosis ATCC
22019).
The 5-substituted derivatives of rhodanine-3-
carboxyalkyl acids dissolved in dimethylosulfoxide
(DMSO), were ﬁrst diluted to the concentration (1000 µg/
mL) in an appropriate broth medium recommended for
bacteria or yeasts. Then, using the same media, serial two-
fold dilutions were made in order to obtain ﬁnal con-
centrations of the tested derivatives ranged from 0.98 to
1000 µg/mL. The sterile 96-well polystyrene microtitrate
plates (Nunc, Denmark) were prepared by dispensing 200 µl
of appropriate dilution of the tested derivatives in broth
medium per well. The inocula were prepared with fresh
microbial cultures in sterile 0.85% NaCl to match the tur-
bidity of 0.5 McFarland standard and 2 μl were added to
wells to obtain ﬁnal density of 1.5× 106 CFU/ml for bac-
teria and 5× 104 CFU/ml for yeasts; CFU—colony forming
units. After incubation (bacterial strains—35 °C for 24 h,
yeast strains—30 °C for 48 h), the MICs were assessed
visually as the lowest concentration of the 5-substituted
derivatives of rhodanine-3-carboxyalkyl acids showing
complete growth inhibition of the reference microbial
strains. Appropriate DMSO control (at a ﬁnal concentration
of 10%), a positive control (containing inoculum without
the tested derivatives) and negative control (containing the
tested derivatives without inoculum) were included on each
microplate.
Minimal bactericidal concentration (MBC) or minimal
fungicidal concentration (MFC) was determined by sub-
culturing 100 μl of the microbial culture from each well that
showed through growth inhibition, from the last positive
one and from the growth control onto the recommended
agar plates. The plates were incubated at 35 °C for 24 h and
the MBC/MFC was deﬁned as the lowest concentration of
the 5-substituted rhodanine-3-carboxyalkyl acids without
growth of microorganisms. Ciproﬂoxacin and vancomycin
were used as the standard drugs (Table 1). Each experiment
was repeated in triplicate. Representative data is presented.
Results and discussion
Chemistry
All the resulting 3-carboxyalkanoic acid derivatives occur-
red as crystalline solids red in colour. They were char-
acterised by high solubility in polar solvents (alcohols,
glacial acetic acid).
The comparison of the condensation reaction yield of all
three groups of the compounds /3a-d/, /4a-c/ and /5a-c/
indicated that 4-N,N-diphenylaminobenzoic aldehyde had
the highest activity in condensation reactions among the
aldehydes used. 4-dibutylaminobenzoic aldehyde was
characterised by the lowest activity.
Table 1 MIC (µg/mL), MBC
















S. aureus ATCC6538 0.49 1.95 4 0.24 0.24 1
S. aureus ATCC25923 0.98 7.81 8 0.49 0.49 1
S. epidermidis
ATCC12228
0.98 0.98 1 0.49 0.49 1
M. luteus ATCC10240 0.12 0.12 1 0.98 1.95 2
B. subtilis ATCC6633 0.24 0.49 2 0.03 0.12 4
B. cereus ATCC10876 0.98 15.6 16 0.12 0.12 1
S. pyogenes ATCC19615 0.24 0.49 2 – – –
S. pneumoniae
ATCC49619
0.24 0.49 2 – – –
S. mutans ATCC25175 0.98 0.98 1 – – –
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The characteristic bands deriving from the stretching
C=O and C=S groups vibrations were present in the IR
spectra of all the researched compounds. The C=O group
vibrations ranged from 1727.9 to 1710.5 cm-1, whereas
C=S group vibrations ranged from 1195.7 to 1184.1 cm-1.
The MS spectra were very simple. The highest intensity
had always the [M+1]+ ion peak. In most cases it reached
100%.
The 1H NMR spectra contained a very characteristic
signal deriving from the proton in =CH–Ar unit. It was a
singlet, which was present in the 7.61–7.76 ppm range of
chemical shifts. Position of the signal from a methine proton
in this range showed that the condensation reaction carried
out to Z isomers (Hardej et al. 2010). The 13C NMR spectra
were characterised by the signal from the carbon atom
bound with exocyclic sulphur atom. It was present in the
192.85–193.38 ppm range of chemical shifts.
Antibacterial activity
The antimicrobial activity of rhodanines has been known
for over 50 years. The design and synthesis of antibacterial
agents based on this heterocycle have been reported in
numerous studies (Pardasani et al. 2001; Grant et al. 2000;
Gandhe and Gautam 2004; Tomasic and Peterlin
Masic 2012). The 5-ylidene-4-thiazolidinones and 4-
thiazolidinone-3-carboxylic acids are the most studied and
promising 4-thiazolidinones in the context of creating new
drug-like molecules (Lesyk and Zimenkovsky 2004; Lesyk
et al. 2011). It was shown that introduction of substituents
(mainly those containing a carboxyl group) in position N3 is
the chemical path to the design of new compounds with a
signiﬁcant biological activity and decreased toxicity (Bhat
et al. 2004). In present study, the antimicrobial assay of the
novel 5-substituted derivatives of rhodanine-3-carboxyalkyl
acids was carried out towards reference strains using a serial
dilution method to obtain the MIC. None of the tested
derivatives had activity against gram-negative bacteria
(Escherichia coli ATCC25922, Salmonella typhimurium
ATCC14028, Klebsiella pneumoniae ATCC13883, Pseu-
domonas aeruginosa ATCC9027, Proteus mirabilis
ATCC12453), and yeasts (Candida albicans ATCC10231,
Candida parapsilosis ATCC22019) (MIC > 1000 µg/mL,
data not shown). Tables 2–4 summarised the results
obtained for the MICs of the 10 target compounds (3a–d,
4a–c, 5a–c) to the gram-positive bacteria: staphylococi
(Staphylococcus aureus ATCC25923, Staphylococcus aur-
eus ATCC6538, Staphylococcus epidermidis ATCC12228);
micrococci (Micrococcus luteus ATCC10240), bacilli
(Bacillus subtilis ATCC6633, Bacillus cereus ATCC10876)
and streptococci (Streptococcus pyogenes ATCC19615,
Streptococcus pneumoniae ATCC49619, Streptococcus



















































































































































































































































































































































































































































































































used as positive controls (Table 1). Mild to moderate
activity (MIC 125–1000 µg/mL) of the all synthesised
derivatives was observed towards streptococci. The new
rhodanine compounds showed different activity from
moderate to very strong against other tested gram-positive
bacteria, i.e., staphylococci, micrococci, and bacilli,
depending on the strain and the synthesised compound. The
ﬁrst group of derivatives /3a–d/ was less active towards the
tested gram-positive strains (MIC 15.6–250 µg/mL) as
compared to the second group /4a–c/ of derivatives (MIC
1.95–7.8 µg/mL) and the third group /5a–c/ of derivatives
(MIC 1.95–15.6 µg/mL). The most active compounds were
/5a/ and /5b/ showing very strong bioactivity with MIC
1.95 µg/mL. The low values of MBC/MIC ratio (2–4) for
/5a/ suggested its bactericidal power in contrast to higher
values (8–16) for /5b/ indicating bacteriostatic activities
except for bactericidal activity of /5b/ against B. subtilis
ATCC 6633 (MBC/MIC 1). The remaining derivatives
showed bactericidal (MBC/MIC ≤ 4) or bacteriostatic
activity against the tested bacteria (MBC/MIC> 4),
depending on the strain and the rhodanine compound.
In the present study, most of synthesised compounds
(4a–c and 5a–c) exhibited strong antibacterial activity
amongst the tested gram-positive bacteria, although the
mechanism of action is not yet clearly understood. How-
ever, rhodanines seem to be inhibitors of the bacterial
enzyme MurB (Andres et al. 2000). The enzyme MurB, an
NADPH dependant enolpyruvyl reductase, is responsible
for the second committed step of bacterial peptidoglycan
biosynthesis; it means that rhodanines could be expected to
be bactericidal. Peptydoglycan is an essential component of
the cell wall of both Gram-positive and Gram-negative
bacteria and enzyme MurB is found in both of them. It
would be expected that rhodanines might possess a broad
Table 3 MIC (µg/mL), MBC (µg/mL) of 4a, 4b, and 4c derivatives towards reference gram-positive bacterial strains



















S. aureus ATCC6538 7.8 15.6 2 3.9 >1000 >256 3.9 >1000 >256
S. aureus ATCC25923 3.9 62.5 16 3.9 >1000 >256 3.9 >1000 >256
S. epidermidis
ATCC12228
3.9 62.5 16 3.9 7.8 2 3.9 >1000 >256
M. luteus ATCC10240 3.9 125 32 3.9 7.8 2 3.9 >1000 >256
B. subtilis ATCC6633 3.9 3.9 1 1.95 3.9 2 1.95 3.9 2
B. cereus ATCC10876 3.9 125 32 3.9 3.9 1 3.9 3.9 1
S. pyogenes ATCC19615 125 >1000 >8 125 500 4 500 >1000 Nd
S. pneumoniae
ATCC49619
125 500 4 125 500 4 500 1000 2
S. mutans ATCC25175 >1000 >1000 Nd 1000 >1000 Nd 1000 >1000 Nd
Table 4 MIC (µg/mL), MBC (µg/mL) of 5a, 5b, and 5c derivatives towards reference gram-positive bacterial strains



















S. aureus ATCC6538 1.95 7.8 4 1.95 31.5 16 15.6 >1000 >64
S. aureus ATCC25923 1.95 7.8 4 1.95 31.5 16 1.95 125 64
S. epidermidis
ATCC12228
1.95 7.8 4 1.95 31.5 16 1.95 125 64
M. luteus ATCC10240 1.95 7.8 4 1.95 15.6 16 3.9 125 32
B. subtilis ATCC6633 1.95 3.9 2 1.95 1.95 1 1.95 1.95 1
B. cereus ATCC10876 1.95 7.8 4 1.95 15.6 8 3.9 62.5 16
S. pyogenes ATCC19615 125 1000 4 125 >1000 >8 125 >1000 >8
S. pneumoniae
ATCC49619
250 500 2 125 500 4 125 500 4
S. mutans ATCC25175 500 >1000 Nd >1000 >1000 Nd >1000 >1000 Nd
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spectrum of antibacterial activity. The differences in bio-
logical activity of rhodanines to gram-positive and
gram–negative bacteria could be explained by the differ-
ences in their cell wall structure and thus in the perme-
ability. Peptydoglycan is major component (90%) of the
gram-positive cell wall, whereas in Gram-negative bacteria,
peptydoglycan, constituting 10% of cell wall, lies between
cytoplasmic membrane and the outer lipid byliayer con-
taining lipopolysaccharide, porins, adhesins which create
additional barrier to cross by.
In this study, the preliminary remarks of the structure
activity dependence can be noted. Comparison the MIC
values determined for the newly synthesised rhodanine
derivatives allowed to state that the basic factor increasing
the activity to prevent bacteria growth is the size of the
substituent at the C-5 position. The number of the carbon
atoms present in the connector between carboxylic group
and the 2,4-thiazolidinedione core is of much less impor-
tance. The inﬂuence of the connector length on the activity
to suppress bacterial growth is noticeable when 5 atoms of
carbon are present in the connector. The derivatives which
have an acetic, propionic and butyric acid fragment at N-3
position and have the same substituent at C-5 position,
demonstrated similar ability to suppress the growth of
Gram-positive bacteria. In many cases the activity was
identical.
Determining the MBC value allowed to establish the
activity to kill bacteria or inhibit its growth. Antimicrobial
agent are usually regarded as bactericidal if MBC value is
higher no more than four times the MIC value (French
2006).
It was established that /5a/ and /4b/ 5-(4′-dibutylamino-
benzylidene)-4-oxo-2-thioxo-3-thiazolidine acetic acid, as
well as 5-(4′-diphenylaminobenzylidene)-4-oxo-2-thioxo-3-
thiazolidine acetic acid and 5-(4′-diphenylaminobenzyli-
dene)-4-oxo-2-thioxo-3-thiazolidine propionic acid had
antibacterial effect on the majority of the gram-positive
bacteria strains.
It was surprising that increasing the number of carbon




A series of new rhodanine-3-carboxyalkyl acid derivatives
possessing p-N,N-benzylidenedialkylamine moieties and p-
N,N-bezylidenediphenylamine as a substituent at the C-5
were synthesised. The compounds were characterised by
antibacterial activity on the tested Gram-positive strains of
bacteria, however without biological activity on gram-
negative bacteria and yeasts.
It was observed that there was a dependency between the
growth of the substituent size at C-5 position of the rho-
danine ring and the antifungal activity growth. The deri-
vatives having a p-N,N-bezylidenediphenylamine fragment
at the C-5 position were characterised by the highest anti-
bacterial activity. The increase of activity was probably
caused by higher hydrophobicity of the aryl groups in
comparison to the alkyl groups, which has been suggested
by previous research (Miao et al. 2013; Patel et al. 2013). It
was also established that the size of the connector between
the carboxylic group and rhodanine ring had a limited
inﬂuence on the antibacterial activity. The results have
indicated the future direction of the research aiming at
synthesis of the compounds characterised by higher anti-
bacterial activity.
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